Johnson & Johnson, US4781601046

Johnson & Johnson stock slips to EUR 256.03, down 1.22%

Published on 11/17/2026 at 08:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson focuses on healthcare innovation, including medicines and treatments for complex diseases. On Xetra, the stock closed at EUR 259.20 on Monday, November 16, 2026.

Healthcare innovation drives the profile

  • Johnson & Johnson focuses on healthcare innovation aimed at preventing, treating and curing complex diseases.
  • The company highlights more than 60 consecutive years of dividend increases.
Johnson & Johnson, US4781601046, Illustration mit AI erstellt.

Johnson & Johnson stock traded at EUR 256.03 on Lang & Schwarz at 08:07 CET on Tuesday, November 17, 2026, 1.22% below the Xetra close of Monday, November 16, 2026, at EUR 259.20.

Healthcare innovation remains central

Johnson & Johnson says its healthcare innovation is aimed at preventing, treating and curing complex diseases. Medicines and less-invasive treatments are among the company’s focus areas, according to its investor-relations site.

Broader market direction can be followed in the S&P 500.

More news and analyses on Johnson & Johnson stock.

Disclaimer...
en | US4781601046 | JOHNSON & JOHNSON | boerse | 70525246 | bgmi